ARS Pharmaceuticals (SPRY) Q4 2025 earnings review
Strong First Year Base Built, But Q4 Seasonality Bites
ARS Pharmaceuticals established a solid foundation in its first full commercial year, generating $72.2M in U.S. net product revenue for its needle-free epinephrine spray, neffy. However, the growth narrative hit a speed bump in Q4: U.S. product sales sequentially reversed 35% to $20.3M from Q3's peak of $31.3M. While management previously telegraphed this as a seasonal dynamic (the broader epinephrine market typically declines post-back-to-school), the steepness of the drop paired with a massive $60.0M quarterly SG&A bill underscores the high cost of customer acquisition. Despite the Q4 revenue contraction, underlying adoption metrics remain healthy—over 22,500 HCPs have now prescribed neffy—and a newly expanded sales force combined with a zero-copay virtual prescribing platform sets the stage for a strong renewal cycle in 2026.
🐂 Bull Case
Over 22,500 healthcare providers have now prescribed neffy, with an impressive 50% repeat prescriber rate. The initial base is established, paving the way for easier renewals in 2026 and 2027.
The 'Get neffy on Us' virtual prescribing platform launched in November is already capturing ~10% of total prescription volume, successfully bypassing doctor-office bottlenecks and prior authorization fatigue.
🐻 Bear Case
With $230.1M spent on SG&A in FY25 to generate $72.2M in U.S. product sales, the DTC marketing model remains highly inefficient. Management is guiding for similar spend in 2026, demanding massive volume acceleration to justify the burn.
The 35% sequential drop in Q4 U.S. product sales proves the brand is still highly vulnerable to seasonal back-to-school swings, complicating the narrative of consistent quarter-over-quarter growth.
⚖️ Verdict: ⚪
Neutral. The underlying product demand and HCP adoption metrics are highly encouraging, but the severe Q4 sequential sales decline and staggering DTC marketing costs prove that penetrating the auto-injector market is a costly, seasonal grind.
Key Themes
Reversing Revenue Trajectory Exposed Vulnerability
After a blockbuster Q3 ($31.3M U.S. product revenue) driven by back-to-school demand, Q4 sales experienced a sharp reversing trend, dropping to $20.3M. While management warned of a ~33% seasonal industry drop in Q3, this highlights that neffy is currently heavily dependent on acute seasonal purchasing rather than steady, year-round uptake. Investors must monitor whether the 'Get neffy on Us' program can smooth out these harsh seasonal peaks and troughs in 2026.
'Get neffy on Us' is a Strategic Moat
Launched in November 2025, this zero-copay virtual provider platform is an accelerating growth driver, already accounting for 10% of total neffy prescription volume. By eliminating the time burden of an office visit (which management previously cited as a primary bottleneck for HCPs who only have 5-7 minutes per patient), ARS is directly targeting the ~13.5M lapsed or non-carrying diagnosed patients. This shifts the point of sale from a burdened allergist to a streamlined digital funnel.
Sales Force Resource Reallocation
ARS is expanding its sales force from 106 to 150 representatives starting in Q2 2026. Crucially, management noted this will be funded through resource reallocation and will not increase planned SG&A expenses. The goal is to increase call frequency on high-prescribing allergists and support staff, signaling a shift from broad awareness to depth of prescribing within core target offices.
DTC ROI Remains Unproven
Total SG&A for FY25 hit $230.1M, primarily driven by the national DTC television and digital campaign. With management committing to a similar annualized spend level in 2026, the company is betting heavily that the awareness generated in 2025 will translate into a massive wave of frictionless renewals in 2026. If those renewals falter or revert to legacy auto-injectors, the current cash burn trajectory is unsustainable long-term.
Urticaria (CSU) Label Expansion Advances
The Phase 2b trial for treating acute flares of chronic spontaneous urticaria (CSU) is actively enrolling across the U.S. and Europe. With interim data expected in H2 2026, this represents a potential $2B+ peak net sales opportunity, fundamentally transforming intranasal epinephrine from an emergency-only allergy safety net into an active disease management tool.
Other KPIs
Cash, cash equivalents, and short-term investments decelerated to $245.0M from $288.2M at the end of Q3 2025. Management asserts this balance is sufficient to fund operations through anticipated cash-flow break-even, negating immediate dilution risks despite the heavy marketing burn.
Accelerating. Up from almost nothing in the first half of the year, driven by partner ALK's rollout in Europe and a $4M regulatory milestone from Pediatrix Therapeutics following approval in China. This validates the global appetite for needle-free alternatives and provides a high-margin revenue stream.
Guidance
Stable. The company is successfully maintaining its gross-to-net retention target of approximately 50%, even while expanding unrestricted payor access and running $0 co-pay programs. This suggests disciplined pricing execution and less reliance on deep discounting.
Stable. Management explicitly stated they remain committed to continued investment in neffy promotion at a 'similar annualized spend level in 2026.' This means investors should model roughly $230M in SG&A for FY26, requiring U.S. product revenue to at least triple to approach operating breakeven.
Key Questions
Seasonality Curve
With the 35% sequential decline from Q3 to Q4, what is the expected revenue trajectory heading into Q1 and Q2 2026? Will we see flat or down sequential growth until the next back-to-school season?
Get neffy on Us Economics
The 'Get neffy on Us' program is driving 10% of prescription volume. Does this channel carry a materially different gross-to-net margin compared to traditional retail prescriptions, given the $0 co-pay and virtual provider costs?
Payer Unrestricted Access Timeline
You noted continued focus on 'securing unrestricted access with the remaining major payors.' What specific percentage of commercial covered lives currently remain restricted via Prior Authorization, and what is the target by year-end 2026?
Sales Force Reallocation
You are expanding the sales force from 106 to 150 reps without increasing overall SG&A. Which marketing or operational channels are having their budgets cut to fund this physical footprint expansion?